Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 03 Dec 2021
AbbVie provides update on Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis in the U.S.
3 December 2021 - AbbVie today announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for ...
Posted by Michael Wonder on 03 Dec 2021
FDA approves pembrolizumab for adjuvant treatment of stage IIB or IIC melanoma
3 December 2021 - On 3 December 2021, the FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of adult ...
Posted by Michael Wonder on 03 Dec 2021
ICMRA and WHO map out flexibilities used by regulators to respond to the COVID-19 pandemic
3 December 2021 - The International Coalition of Medicines Regulatory Authorities and the World Health Organisation have reviewed some of ...
Posted by Michael Wonder on 03 Dec 2021
FDA approves rituximab plus chemotherapy for paediatric cancer indications
3 December 2021 - On 2 December 2021, the FDA approved rituximab (Rituxan, Genentech) in combination with chemotherapy for pediatric ...
Posted by Michael Wonder on 03 Dec 2021
Agenda for the December 2021 PBAC intracycle meeting
3 December 2021 - The agenda for the December 2021 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 03 Dec 2021
TOT Biopharm announces NMPA granted marketing approval for Pusintin (TAB008, bevacizumab) in China
1 December 2021 - TOT Biopharm announced its self-developed Pusintin (TAB008, bevacizumab) has been officially granted approval by the National ...
Posted by Michael Wonder on 03 Dec 2021
ZetaMet receives breakthrough device designation from U.S. FDA for treatment of metastatic bone cancers
1 December 2021 - The technology is a first of its kind molecular pathway designed to suspend cancer, inhibit pain, and ...
Posted by Michael Wonder on 03 Dec 2021
ATAGI update following weekly COVID-19 meeting (1 December 2021)
3 December 2021 - On 1 December 2021 ATAGI reviewed the latest developments relating to COVID-19 and COVID-19 vaccine safety. ...
Posted by Michael Wonder on 02 Dec 2021
MHRA grants conditional marketing authorisation for COVID-19 treatment Xevudy (sotrovimab)
2 December 2021 - A supply agreement reached with UK government will enable access to sotrovimab for UK patients. ...
Posted by Michael Wonder on 02 Dec 2021
Harmonisation of health technology assessment across the European Union: lessons for the United States
2 December 2021 - In the multi-payer US system, each public program, private insurer, and self-insured employer conducts its own ...
Posted by Michael Wonder on 02 Dec 2021
PHARMAC in review (2021) - part 2
3 December 2021 - As expected, the interim report fails to address the elephant in the room. ...
Posted by Michael Wonder on 02 Dec 2021
Call for a central portal for clinical study reports
1 December 2021 - In an open-access publication in the Journal of European CME, two authors from IQWiG argue that ...
Posted by Michael Wonder on 02 Dec 2021
Investors say drug pricing measure may shift incentives for biotech venture funding
2 December 2021 - Some analysts say bill would discourage investment in drugs taken as pills. ...
Posted by Michael Wonder on 02 Dec 2021
EMA starts rolling review of Valneva’s COVID-19 vaccine (VLA2001)
2 December 2021 - The EMA’s CHMP has started a rolling review of VLA2001, a COVID-19 vaccine being developed by ...
Posted by Michael Wonder on 02 Dec 2021
Strengthening patient access to new medicines through new landmark Bill
2 December 2021 - Australians will see improved access to new and innovative medicines, vaccines and treatments as a landmark ...